Samir Parekh, MBBS Hematology-Oncology, Cancer Director of Translational Research in Myeloma and Co-leader of the Cancer Clinical Investigation program The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai

06 Sep T-Cell Sequencing May Allow Relapsed Multiple Myeloma Patients to Respond to Further Therapies

Posted at 15:27h in Author Interviews, Cancer Research, JAMA by

MedicalResearch.com Interview with:

Samir Parekh, MBBS Hematology-Oncology, Cancer Director of Translational Research in Myeloma and Co-leader of the Cancer Clinical Investigation program The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai

Dr. Parekh

Samir Parekh, MBBS
Hematology-Oncology, Cancer
Director of Translational Research in Myeloma and
Co-leader of the Cancer Clinical Investigation program
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Clinical outcomes for myeloma patients patients have improved significantly over the past decade with the introduction and success of newer immunomodulatory treatments such as CART cell therapy and bispecific antibodies. Strategies are needed to determine the best treatment options for patients relapsing or unresponsive to initial courses of these types of therapies.

We analyzed the outcomes of patients relapsing after bispecific antibody therapy for myeloma. Our data shows that sequencing of bispecific antibodies or CART after initial bispecific failure can effectively salvage patients and lead to excellent outcomes in myeloma. This provides the foundation for future studies combining this new class of immunotherapy with CART or additional bispecific antibodies to improve outcomes in myeloma.
MedicalResearch.com: What are the main findings?

Response:  Patients relapsing after an initial bispecific therapy can still respond to a second bispecific or CART and have excellent long-term survival. Future trials incorporating sequential combinations of these agents will improve long term outcomes for myeloma.

MedicalResearch.com: What should readers take away from your report?

Response: Correlative studies analyzing T cell activation and exhaustion with these sequential therapies are ongoing.

Disclosures: S.P. received advisory board fees from GRAIL and research support from Celgene/Bristol Myers Squibb, Amgen, and Karyopharm

Citation:

Tarek H. Mouhieddine, Oliver Van Oekelen, David T. Melnekoff, Jeanne Li, Yogita Ghodke-Puranik, Guido Lancman, Santiago Thibaud, Darren Pan, Sridevi Rajeeve, Sarita Agte, Adolfo Aleman, Larysa Sanchez, Shambavi Richard, Adriana Rossi, Joshua Richter, Hearn Jay Cho, Cesar Rodriguez, Alessandro Lagana, Erin Moshier, Ajai Chari, Sundar Jagannath, Samir Parekh,

Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients,Blood Advances, 2022,,ISSN 2473-9529,

https://doi.org/10.1182/bloodadvances.2022007923.

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

 

Last Updated on September 6, 2022 by Marie Benz MD FAAD

1,161
Tags:
, , ,